New investigations on retatruded, a dual agonist for glucagon-like peptide-1 and gastric inhibitory polypeptide, demonstrate significant results in addressing excess body fat and type 2 diabetes. Preliminary information from clinical assessments reveal substantial reductions in body mass and bett